Zealand Pharma Will Test European IPO Market
This article was originally published in The Pink Sheet Daily
The Danish biotech hopes to tempt investors with revenue prospects from its late-stage GLP-1 analog, partnered with Sanofi-Aventis.
You may also be interested in...
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes
Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.